The conflict of interest the field doesn't want to discuss

The dominant business model in longevity medicine, since at least 2020, has been to combine a comprehensive diagnostic workup with an in-house treatment programme. The diagnostic identifies a marker outside the optimal range. The treatment programme — peptide protocol, hormone optimisation, hyperbaric oxygen, IV infusions, sometimes regenerative therapies — corrects it. The same clinic earns from both.

The patient is told this is integrated care. The marketing presents it as convenience: one clinic, one team, one treatment plan, full continuity. We agree the convenience is real.

The incentive geometry, separately, is broken. And it deserves to be discussed in plain language.

What conflict of interest looks like in this category

A clinic that profits from prescribing what it diagnoses has a structural financial incentive to find protocols. Not for any specific patient — the individual clinician you sit across from is, in our experience, mostly trying to do the right thing — but at the level of the practice. The business unit grows by selling more treatment. The diagnostic step is the funnel.

Three patterns we see across the directory.

The detection-into-protocol pattern. A finding on the workup — slightly elevated inflammation, slightly low testosterone, slightly suboptimal mitochondrial markers — is translated into a treatment recommendation that the same clinic then bills for. The translation may be defensible. The financial geometry is not neutral.

The membership treadmill pattern. A membership-style concierge clinic that bundles diagnostics with a treatment ladder. Year one buys the deep workup. Year two buys the ongoing peptide infusions. Year three the hormonal management. Year four the regenerative protocol. The clinic remains continuously paid; whether the patient continuously benefits is a separate question.

The flagship-treatment pattern. A residential clinic with a signature treatment — cellular therapy, a proprietary infusion, a branded regenerative protocol — administered to patients who came in for the diagnostic. The signature treatment may have decades of refinement. The randomised evidence for the longevity claim may be substantially weaker than the marketing implies.

A worked example

Consider what the diagnose-and-prescribe geometry actually looks like inside one of the older residential clinics. The patient arrives for a week. Day one is the workup: blood panels, body composition, cardiopulmonary testing, often imaging, often a stress assessment, sometimes a sleep study. Day two is the results review. The clinician sits across from the patient with the findings: borderline-elevated inflammation, slightly suboptimal hormonal markers, a few imaging incidentals worth tracking, mild glycaemic variability on the continuous monitor. None of it is acutely alarming. All of it is actionable — meaning a protocol can be prescribed for each finding.

From day three the protocols begin. IV nutrient infusions for the inflammation. A short course of hormonal optimisation, started before the patient leaves. Hyperbaric oxygen sessions for the cellular function findings. A peptide course for the recovery profile. A six-month follow-up package to monitor “response.” Each protocol is sensible in isolation. Each is billed.

By the end of the week the patient has paid for the workup, the in-stay treatment, the discharge supplement pack, and a follow-up subscription that ports the protocol back home. The clinical case for each line item is at least defensible. The structural fact is that every line item flows to the same balance sheet. The diagnostic was the funnel; the protocols are the revenue.

A different clinic, running the same workup, with no in-house treatment capability, would have ended the week with the workup priced and a written referral to a specialist for the two findings worth following. The patient would have left poorer in protocol but richer in clarity. Both outcomes are clinically defensible. Only one of them grows the originating clinic’s annual revenue per patient.

We are not arguing the first model is malpractice. We are arguing that the incentive geometry is loaded — and that across thousands of patients and many years it produces a different aggregate pattern of prescribing than the second model would, even when staffed by clinicians of identical good faith.

Why this matters more than the marketing suggests

Two reasons.

First, the patient is paying tens of thousands of dollars across a year of care. The compounding effect of small protocol decisions — do you need this peptide course, this hormone replacement, this monthly infusion — is enormous. A clinic with a structural incentive to add protocols will, on average and over time, add more protocols than a clinic without that incentive.

Second, the published evidence base for many of the treatments in question is weaker than the marketing implies. Off-label peptide protocols, certain hormone optimisations, hyperbaric oxygen for non-clinical indications, cellular and regenerative therapies — the gap between the marketing copy and the randomised data is, in places, sizeable. The clinic that profits from prescribing has the structural incentive to maintain that gap; the clinic that profits from diagnosing alone does not.

The clinics that have built around the conflict

Three structural answers exist, and we credit each.

The pure diagnostic clinic. YEARS in Berlin is the cleanest example: the clinic charges for the diagnostic day and refers any treatment recommendation outside its own walls. There is no in-house pharmacy, no peptide infusion suite, no hormone management division. The financial incentive is the day, not the year of follow-on prescriptions. The model is replicable; we expect to see more of it.

The imaging-only practice. Prenuvo, at scale, runs only the imaging service. Findings flow back to the patient’s existing physician network for clinical action. The clinic that scans does not benefit from any treatment that follows. The trade-off is a thinner diagnostic — imaging-only is not a full longevity workup — but on the conflict axis the geometry is unusually clean.

The hospital-based programme. Hirslanden in Zürich and Sheba Longevity Center in Israel run longevity programmes inside larger academic medical centres. Treatments that follow from the workup are dispensed by the broader hospital system rather than billed as bespoke longevity protocols. The clinical incentive structure of a research hospital is materially different from that of a standalone longevity practice; we credit this.

The longitudinal membership model. Early Medical (Peter Attia’s small-panel concierge practice) and Biograph (a larger membership clinic with the same diagnose-first instinct) run membership concierge models, but with the membership itself as the revenue line rather than treatment-by-treatment billing. The pressure is meaningfully lower than in the protocol-treadmill model. Specialists, when needed, are referred outside the membership.

These are not perfect solutions. A pure diagnostic clinic still wants you to come back next year. A membership clinic still benefits from you renewing. But the geometry is a sharp step removed from the diagnose-then-prescribe model, and the difference shows up in the editorial behaviour: more honest framing of what a finding actually warrants, less reliable enthusiasm for the latest peptide.

When the combined model genuinely makes sense

The argument above is not that diagnose-and-treat under one roof is always wrong. It is that the incentive structure is loaded, and that the loading needs naming. There are three patient profiles for whom we think the combined model is, on balance, the right choice.

The patient with an active clinical finding that the workup uncovers — a frank deficiency, an early-stage condition, a measurable risk that needs treatment now — is better served by a clinic that can begin care the same week. The hand-off from a diagnostic-only clinic to a treating physician adds a delay that, for an active finding, is the wrong trade.

The patient who is geographically distant from a strong specialist network — outside a major metropolitan area, in a region without good outpatient longevity care, or travelling for the workup from another country — is better served by a clinic that can contain the full care pathway. The referral pathway only works if there are physicians to refer to.

The patient who has tried the diagnostic-only model and found that the discipline of executing on findings outside a structured clinical relationship simply does not happen — that the workup landed, the recommendations were sensible, and a year later very little changed — may be better served by the higher friction and tighter accountability of a membership model. The honest fee is the price of follow-through.

We score for the structural incentive because most readers are not in those three buckets. Most readers are mid-career, urban, capable of executing on a written plan, and underserved by the protocol upsell that the standard model produces. For them, the diagnose-then-refer geometry is straightforwardly better.

What this means for the reader

Three operating positions we hold.

Read the financial geometry first. Before you read the menu, look at how the clinic earns its revenue. If it earns from the workup and the treatments and the memberships and the supplements, you are inside a structural conflict. If it earns from one of these and refers the rest, you are not.

Treat the upsell conversation as the test. At every clinic that combines diagnosis and treatment, the conversation that follows the workup is where the incentive geometry shows up. Some clinicians, in good faith, push back against unnecessary protocols. Others do not. The hour after results is the most informative hour of the visit.

The price of a treatment is not the cost of the treatment. A €4,000 NAD+ infusion course is not a $200 vial of NAD+ delivered by a nurse. It is the result of the clinic’s entire economic structure pricing this protocol against your willingness to pay. The conversion rate from diagnosis to protocol matters; the markup matters; the alternative protocols available outside this clinic at lower cost matter.

The editorial position

We score conflict freedom as one of four 25-point axes in our editorial rubric, and we do so because we believe it is the single most predictive variable for whether a clinic is ultimately serving the reader rather than itself.

This is not a moral indictment. It is a structural observation. A clinic with built-in incentives to add protocols will, on average, add more. A clinic without those incentives will not. The financial geometry runs faster than any individual clinician’s good intentions.

We will continue to credit clinics that have engineered around the conflict. We will continue to deduct points from those that have not. This is the line we will not move on.

Compare quietly. Choose well. Look at the incentive structure before the menu.